Amundi Asset Management US’s Harvard Bioscience HBIO Stock Holding History

Amundi Asset Management US’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,490	Closed	-$78K	–	1625
2018 Q3	$78K	Hold	1,490	–	–	﹤0.01%	1539
2018 Q2	$80K	Buy	+1,490	New	+$76.3K	﹤0.01%	1480

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Amundi Asset Management US's HBIO Position: Q4 2018 in Review

Amundi Asset Management US sold out of Harvard Bioscience (HBIO) in Q4 2018, closing a stake of 1,490 shares — an estimated $78K sold.

Amundi Asset Management US first reported a position in HBIO in Q2 2018 and held it in 2 quarters. The position peaked at $80K in Q2 2018. 80 funds tracked by Wall St. Rank hold HBIO as of Q4 2018.

Amundi Asset Management US reported no remaining Harvard Bioscience position as of Q4 2018 after selling out during the quarter.
Amundi Asset Management US sold 1,490 Harvard Bioscience shares in Q4 2018, an estimated $78K.
Amundi Asset Management US first reported a position in Harvard Bioscience in Q2 2018 and held it in 2 quarters.
Amundi Asset Management US's Harvard Bioscience position peaked at $80K in Q2 2018.
80 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.